After the success of last year's virtual event, we're excited to announce a return to an in-person occasion this year at our London office.
Join us for a day exploring the legal and commercial issues that matter most to pharmaceutical and biologics companies across the UK and Europe.
We have broadly split the day's content into two parts. Over the course of the morning, we will lead with the hot issues around intellectual property in pharma. The afternoon will see discussion focusing on broader commercial and regulatory issues. Depending on your areas of interest, please select from the RSVP whether you are interested in attending some or all of the day.
In addition to our specialist panel of speakers and contributors, we are also delighted to announce that Hannah Kuchler, global pharmaceuticals correspondent for the FT will be co-chairing the day alongside our Head of International Life Sciences, Alison Dennis. Hannah will of course be contributing her unique insights throughout the day and we are delighted to say, she has also agreed to deliver a thought-provoking and interesting keynote after lunch.
We look forward to welcoming you to our offices for this not to be missed event on Thursday 22 September.
|09:45||Compulsory licensing in Europe – quick but not easy; what are the alternatives?|
|10:15||Rare diseases: exclusivity protection and its limits for therapeutic products in this area|
|11:15||The Unified Patent Court and Unitary Patent: discussing the big strategic questions|
|12:00||Preparing your company for an exit|
|13:35||Keynote speech by Hannah Kuchler, global pharmaceuticals correspondent, Financial Times|
|14:00||M&A in pharmaceuticals|
|14:15||Collaborating with an AI company to identify molecules or targets. Who should own what? How do you structure the royalties/milestones?|
|14:35||Latest from the EU and UK on data privacy regulations|
|15:15||How do we get vital disease education/information out to populations through the use of digital marketing tools such as social media and other specific apps? What are the legal implications and how do these rules compare in different countries?|
|16:00||Enforcement activity on advertising and promotion, bribery and corruption|
|16:30||Early access schemes and how they compare across different countries|
|17:15||Closing remarks followed by drinks and canapes|
Kilburn & Strode - Partner
Elizabeth works with her clients to propose patent protection strategies, including invention capture and patent portfolio management. She also provides advice on third party patents/ applications including patent landscaping and providing infringement and validity opinions.
She has particular experience in opposition and appeal proceedings before the European Patent Office.
Elizabeth works in all areas of chemistry including pharmaceutical chemistry. She has particular experience in working in the area of industrial chemistry, particularly on low Global Warming Potential fluorocarbons, materials for films and coatings, polymers, catalysts, solvents, refrigerants, foam blowing agents, security markings, propellants and large scale synthetic processes.
Elizabeth works for a variety of companies, from universities and spin-out companies through to blue-chip multinational corporations.
Financial Times - Global pharmaceuticals correspondent
In the US, Kuchler collaborated with PBS Frontline on a documentary about the opioids crisis, which was nominated for an Emmy and won a Loeb award. She has worked for the FT for twelve years in London, Hong Kong, New York, and San Francisco.
If you have any questions please use the following details: